NPI: 1962851006 · TITUSVILLE, FL 32780 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 06/09/2016
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 06/09/2016 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,477 | $831K |
| 2019 | 12,090 | $2.20M |
| 2020 | 15,779 | $3.05M |
| 2021 | 4,728 | $279K |
| 2022 | 1,897 | $266K |
| 2023 | 2,296 | $125K |
| 2024 | 798 | $40K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 12,526 | 498 | $2.44M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 15,629 | 1,066 | $2.30M |
| J1270 | Injection, doxercalciferol, 1 mcg | 6,228 | 402 | $1.05M |
| A4657 | Syringe, with or without needle, each | 1,607 | 565 | $417K |
| J1756 | Injection, iron sucrose, 1 mg | 1,729 | 330 | $176K |
| 85048 | 507 | 339 | $93K | |
| 85041 | 509 | 340 | $93K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 452 | 275 | $72K |
| 83970 | 345 | 211 | $64K | |
| 83540 | 175 | 114 | $30K | |
| 83550 | 124 | 84 | $26K | |
| 82728 | 156 | 102 | $25K | |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 33 | 12 | $2K |
| 82607 | 15 | 12 | $2K | |
| 82746 | 15 | 12 | $2K | |
| 82108 | 15 | 12 | $2K |